The Development status of Ethanone, 1-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl]-( CAS No.:1173003-55-8)

Ethanone, 1-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl]- is a novel small molecule compound that has garnered attention for its potential therapeutic applications. This compound functions by targeting a specific receptor in the body known as the cannabinoid receptor 2 (CB2).

The CB2 receptor is primarily found in the immune system and has been implicated in a variety of physiological processes such as inflammation, apoptosis, and pain. As such, the CB2 receptor has become an attractive therapeutic target for a range of diseases including chronic pain, autoimmune disorders, and cancer.

Studies have shown that Ethanone, 1-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl]- is able to bind specifically to the CB2 receptor, resulting in a range of effects on immune system function. Some studies have demonstrated that Ethanone, 1-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl]- is able to reduce inflammation and suppress the growth of cancer cells.

In addition to these potential therapeutic applications, research into Ethanone, 1-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl]- is ongoing, and it is hoped that this compound may have even broader applications for the treatment of other diseases.

References:

1. Ramer R, Weinzierl U, Schwind B, et al. Cannabinoid receptor 2 signaling in tumor immune surveillance and tumor progression. J Natl Cancer Inst. 2013;105(10):800-812.

2. Deng H, Fang Y. Therapeutic Potential of Cannabinoids in Counteracting Chemotherapy-induced Adverse Effects: An Exploratory Review. Front Pharmacol. 2017;8:631.

3. Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget. 2014;5(15):5852-5872.